ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMB Imperial Brands Plc

1,827.50
23.00 (1.27%)
25 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Imperial Brands Plc LSE:IMB London Ordinary Share GB0004544929 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  23.00 1.27% 1,827.50 1,823.50 1,824.50 1,826.00 1,796.50 1,805.00 10,841,971 16:35:13
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Cigarettes 32.48B 2.33B 2.6392 6.91 16.09B

Cigarette Maker Imperial Bets on Medical Cannabis

28/06/2018 5:00pm

Dow Jones News


Imperial Brands (LSE:IMB)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Imperial Brands Charts.
By Saabira Chaudhuri 

LONDON -- Imperial Brands PLC, the owner of Winston and Maverick cigarettes, bought a minority stake in Oxford Cannabinoid Technologies, a U.K.-based startup focused on research into medical uses of cannabis.

The investment marks the latest move by the world's biggest tobacco and alcohol companies to explore opportunities from the widening acceptance of the drug.

The London-based company, formerly known as Imperial Tobacco, is contributing about GBP10 million ($13.1 million) in a funding round for the firm, according to a person familiar with the deal. The money will be used to research how cannabinoids can be used to treat conditions including pain, inflammation, cancer and neurological disorders. Cannabinoids are the chemical constituents of cannabis.

Cowen analyst Vivien Azer described the investment as "the most significant move among the global tobacco players in the cannabis industry to date."

As a number of U.S. states and other countries have legalized cannabis use or liberalized regulation, tobacco and alcohol industry executives have viewed the drug as a potential competitor to their own products. Canada recently moved to legalize recreational marijuana. California in January implemented new rules allowing recreational marijuana sales and the drug's commercial regulation.

Imperial said its interest in cannabis is limited to medical uses. The company's chief development officer, Matthew Phillips, said the deal would help Imperial build a deeper understanding of the medical cannabis market.

Heineken NV on Tuesday said its Lagunitas beer brand would this month launch a new line of nonalcoholic sparkling water in California, infused with tetrahydrocannabinol and a combination of THC and cannabidiol. Both are cannabinoids present in cannabis. The company promises "the chill of sun-grown cannabis."

Last year, Constellation Brands Inc., the U.S. distributor of Modelo and Corona, took a stake in a Canadian marijuana company, and said it plans to work with the grower, Canopy Growth Corp., to develop and market cannabis-infused beverages.

Write to Saabira Chaudhuri at saabira.chaudhuri@wsj.com

 

(END) Dow Jones Newswires

June 28, 2018 11:45 ET (15:45 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

1 Year Imperial Brands Chart

1 Year Imperial Brands Chart

1 Month Imperial Brands Chart

1 Month Imperial Brands Chart

Your Recent History

Delayed Upgrade Clock